Organizer

Ignacio Melero is a full Professor of Immunology at the Universidad de Navarra, Spain, and in 2015 was appointed co-head of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra. Dr Melero earned his medical degree from the Universidad de Navarra and completed his residency training in Clinical Immunology at the Hospital Universitario de la Princesa, Madrid. In 1994, Dr Melero joined Bristol-Myers Squibb, Seattle, USA, as a researcher in cancer immunotherapy, where he contributed to pioneering publications in the field of co-stimulation of antitumour immune responses and the use of immunostimulatory monoclonal antibodies such as anti 4-1BB (CD137). In 2018, Dr Melero was appointed corresponding academic of the Spanish Royal National Academy of Medicine. Dr. Melero also serves part-time as a professor of Oncology at the University of Oxford.

Dr Melero’s research interests focus on translational research with cell, gene and monoclonal antibody-mediated strategies of immunotherapy for cancer. Dr Melero has acted as Principal Investigator in over 61 cancer immunotherapy pharmaceutical industry-sponsored clinical trials. He has authored more than 350 publications and serves as Deputy Editor for Clinical Cancer, Research Scientific Editor for Cancer Discovery, Associate Editor for Frontiers in Immunology and Section Editor for the Journal for Immunotherapy of Cancer.

« Go Back